Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Head-to-head longitudinal comparison of two mass spectrometry-based methods for monitoring monoclonal proteins in multiple myeloma: Analytical and clinical insights from the GEM-CESAR trial

View Full Paper
Ask AI
Bookmark
Share

Authors

RRRafael RíosCPChai W. PhuaSLSunil Lakhwani

Discussion

Loading...

Member takes

Overview

Longitudinal analysis shows improved progression-free survival in double-negative multiple myeloma cases, indicating better disease monitoring.

Key Points

  • This research aims to compare two mass spectrometry techniques for monitoring monoclonal proteins in multiple myeloma.
  • Analyzed 55 serum samples from 18 patients with high-risk smoldering multiple myeloma.
  • Methods included MALDI-TOF and LC-Q/TOF mass spectrometry.
  • Used next-generation flow for measuring residual disease in bone marrow samples.
  • LC-MS showed greater sensitivity for detecting monoclonal proteins compared to Exent.
  • Concordance rates varied by treatment phase: 72.7% overall, with reduced samples post-consolidation.
  • Double-negative patients exhibited significantly longer progression-free survival compared to other groups.

Cite This Study

Ríos et al. (2025) studied this question.

synapsesocial.com/papers/693624d74fa91c937236d0c2https://doi.org/10.1182/blood-2025-2238
View Full Paper
Ask AI
Bookmark
Share